Chen R - Search Results

1

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Among authors: chen l, chen r. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.

2

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

Chen R, Palmer JM, Popplewell L, Shen J, Smith E, Delioukina M, Kogut N, Rosenthal J, Forman S, Nademanee A. Chen R, et al. Ann Hematol. 2011 Jul;90(7):803-8. doi: 10.1007/s00277-010-1146-3. Epub 2011 Jan 6. Ann Hematol. 2011. PMID: 21210120

3

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

Tiemann K, Alluin JV, Honegger A, Chomchan P, Gaur S, Yun Y, Forman SJ, Rossi JJ, Chen RW. Tiemann K, et al. Leuk Lymphoma. 2011 Nov;52(11):2148-54. doi: 10.3109/10428194.2011.593272. Epub 2011 Jul 12. Leuk Lymphoma. 2011. PMID: 21745168 Free PMC article.

4

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, Snyder D, Conrad J, Lacey SF, Frankel P, Dagis A, Nademanee A, Forman SJ. Kirschbaum MH, et al. Among authors: chen r. Biol Blood Marrow Transplant. 2012 Mar;18(3):432-40. doi: 10.1016/j.bbmt.2011.07.017. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801703 Free article. Clinical Trial.

5

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: chen r. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.

6

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK. Chen R, et al. Blood. 2012 Jun 28;119(26):6379-81. doi: 10.1182/blood-2012-03-418673. Epub 2012 May 18. Blood. 2012. PMID: 22611160 Free PMC article.

7

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.

Zhou J, Tiemann K, Chomchan P, Alluin J, Swiderski P, Burnett J, Zhang X, Forman S, Chen R, Rossi J. Zhou J, et al. Among authors: chen r. Nucleic Acids Res. 2013 Apr;41(7):4266-83. doi: 10.1093/nar/gkt125. Epub 2013 Mar 6. Nucleic Acids Res. 2013. PMID: 23470998 Free PMC article.

8

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Mei M, Thomas S, Chen R. Mei M, et al. Among authors: chen r. BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7. BioDrugs. 2014. PMID: 24258497 Free PMC article. Review.

9

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Siddiqi T, Thomas SH, Chen R. Siddiqi T, et al. Among authors: chen r. Pharmgenomics Pers Med. 2014 Feb 20;7:79-85. doi: 10.2147/PGPM.S57700. eCollection 2014. Pharmgenomics Pers Med. 2014. PMID: 24672256 Free PMC article. Review.

10

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. Chen R, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1864-8. doi: 10.1016/j.bbmt.2014.06.037. Epub 2014 Jul 5. Biol Blood Marrow Transplant. 2014. PMID: 25008328 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23,225 results

Search Page